Lumasiran: Latex Content

The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.

The full Prescribing Information for OXLUMO® (lumasiran) is provided here. Alnylam Pharmaceuticals does not recommend the use of its products in any manner that is inconsistent with the approved Prescribing Information. This resource may contain information that is not in the approved Prescribing Information.

If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at RNAiScience.com.

INDEX

DRUG PRODUCT CONTAINER

Lumasiran drug product is supplied in a single-use Type I clear glass vial with a fluoropolymer-coated bromobutyl rubber stopper and an aluminum overseal with a flip-off button. The stopper is not made with natural rubber latex or dry natural rubber.[1,2]

OXLUMO PRESCRIBING INFORMATION – RELEVANT CONTENT

The DESCRIPTION section provides the following information[3]:

> *OXLUMO is supplied as a sterile, preservative-free, clear, colorless-to-yellow solution for subcutaneous administration containing the equivalent of 94.5 mg of lumasiran (provided as lumasiran sodium) in 0.5 mL of water for injection and sodium hydroxide and/or phosphoric acid to adjust the pH to ~7.0.*

ABBREVIATIONS

mL = milliliter; mg = milligram.

Updated 26 June 2024

REFERENCES

1. Alnylam Pharmaceuticals. Data on file. MED-ALL-GO1-2000062.
2. West Pharmaceutical Services, Inc. Data on file. MED-ALL-GO1-2000130.
3. OXLUMO (lumasiran) Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals.